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COVID-19 has reached pandemic levels in March 2020 and impacted public health with 
unpredictable consequences.1, 2 The conduct of clinical research in areas unrelated to COVID-
19 has been disrupted and will be further affected.  Researchers, trial participants and study 
personnel have to overcome challenges to sustain proper and safe conduct of clinical trials 
(i.e. logistical challenges, lower enrollment than expected, difficulties in follow-up and 
outcome assessment/adjudication, incomplete data collection, research funding 
prolongation).1 Of obvious concern are the risks of SARS-CoV-2 infection in study individuals 
as well as the corollary effects of broader health care consequences related to the global 
protective measures (i.e. health-care access for events unrelated to COVID-19, mental health 
conditions), which may act as competing risks and result in adverse clinical outcomes 
unrelated to trial’s intervention(s) and conditions. 
Accumulated evidence supports that SARS-CoV-2 is more frequently observed and 
associated with impaired prognosis in elderly, patients with cardiovascular disease (CVD) 
and related comorbidities.3 Against this complex multidimensional crisis, we wonder in 
which extent contemporary randomized clinical trials (RCTs) in cardiovascular field can be 
potentially affected and are prepared to address such challenges; since trials’ participants 
may be subject to events entirely different in nature (competing risks) owing to intrinsic 
vulnerability but also to corollary health effects of the global protective measures.  
Methods
All data are available upon request.
We considered protocols of RCTs dealing with cardiovascular conditions in adults during the 
last 3 years (March 31, 2017 to March 31, 2020); a time-span that allowed us to capture 
contemporary ongoing trials. We focused only on peer-reviewed protocols published in 
PubMed in English to ensure clarity of required information. Protocols provided the 
recruitment and follow-up period were considered, if the cumulative time-period was 
overlapping and inclusive of the COVID-19 pandemic (later than January 01, 2020). The 
following search-terms were used: “random*”, “study design”, “protocol”, “cardiac”, 
“valvular”, “heart”, “coronar*”, “arrhythm*”. The periods of recruitment and follow-up were A
cc
ep
te
d 
A
rt
ic
le
D
ow
nloaded from
 http://ahajournals.org by on O
ctober 27, 2020
This article is protected by copyright. All rights reserved
extracted along with trials’ characteristics. We also collected whether adaptive or analyses 
accounting for competing risks and methods to address incomplete data collection had been 
considered. Due to the nature of our study, no institutional review board approval was 
required. 
Results
We identified 155 peer-reviewed protocols of unique RCTs in cardiovascular medicine 
fulfilling our inclusion criteria. The median (interquartile range) period of recruitment is 32 
(23–46) months, ranging between the years 2014 and 2024.  Follow-up duration among the 
trials has a median (interquartile range) of 12 (6–24) months (1 to 60 months) (Figure 1). 
The vast majority are multicenter studies (78%) recruited patients in Africa, Asia, Australia, 
Europe, and North America. Non-industry related funding sources are disclosed in 96 (62%) 
protocols. The median sample size reports 360 (144–1391) patients ranging from 24 to 
32,000 individuals. RCTs with larger sample size report prespecified longer follow-up 
periods (p=0.002) (Figure 1). Strategies under investigation are drugs (58 (37%)), 
participative interventions (34 (22%)), surgical or minimal invasive interventions (31 
(20%)), diagnostic tests (13 (8%)) and diverse (19 (12%)). The primary outcome is a 
composite endpoint in 60 trials (39%); all-cause mortality is component of it in 38 trials and 
infection in only 2 trials. All-cause mortality is the single primary outcome in 8 trials. An 
adaptive analysis plan is mentioned only in 2 trials, and survival analysis accounting for the 
competing risk of death is mentioned only in 7 trials. Methods to deal with missing data 
were reported only in 38 out of 155 (25%) of the trials’ protocols.
Discussion
In a representative sample of contemporary ongoing RCTs in cardiovascular medicine, one 
third of the trials include all-cause mortality or infection-related events as part of the 
primary endpoint. An adaptive or competing risk analysis has been considered upfront by 
the investigators in less than 6% of the sample. Current projections of the future dynamics of 
SARS-CoV-2 infection suggest recurrent but less severe wintertime outbreaks,4 which will 
further challenge the flow of clinical research; whereas accumulated evidence during the 
first wave of the COVID-19 pandemic suggest that the increased mortality may also be A
cc
ep
te
d 
A
rt
ic
le
D
ow
nloaded from
 http://ahajournals.org by on O
ctober 27, 2020
This article is protected by copyright. All rights reserved
attributed to causes other than the infection.5 Above projections and observations suggest 
that researchers may face considerable challenges under the current circumstances in terms 
of continuation of clinical trials (i.e. nonadherence, lower recruitment rates, limited funding 
sources), achieving prespecified sample sizes during the recruitment period, appropriately 
follow-up trials’ participants (alternative practices may be required i.e. visits through 
remote connections), and analyzing the acquired data (i.e. impact of competing events, 
inappropriate outcome adjudication). More specific, researchers may have to adopt the 
prespecified analysis plan of RCTs to address considerable imbalances between treatment 
arms, incomplete data collection, and to derive complementary information by applying 
competing risk models (joint hazard models for all of the different types of events) that 
properly account for competing risks for time-to-event primary outcomes analyses. Of note, 
such considerations are equally applicable to any research field dealing with extremely 
vulnerable patient-groups and high-risk features (i.e. patients with malignancies).
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Figure Legend:
Figure 1. Distribution of 155 ongoing contemporary clinical trials over time in 
cardiovascular medicine overlapping with the COVID-19 pandemic. Each circle 
represents a clinical trial and it is weighted according to the respective sample size of the 
trial. Trials shown overlap with the COVID-19 pandemic either with respect to recruitment 
periods and/or follow-up duration. X-axis corresponds to the midpoint of the recruitment 
period of each trial. Y-axis corresponds to the planned follow-up duration (months). The 
dark red continuous line represents a smooth line (non-parametric) through the scatter plot 
(locally weighted scatterplot smoothing) to illustrate the relationship between the two 
variables and foresee any potential trends over time. 
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